Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
U.K. Dividend Stocks Portfolio Review: Summer 2023
07:49pm, Wednesday, 23'rd Aug 2023
The UK Dividend Stocks Portfolio invests exclusively in dividend-paying FTSE All-Share stocks. Short-term returns can be extremely misleading because they are driven by the emotional ups and downs of
AstraZeneca facing two London lawsuits over COVID-19 vaccines
11:17am, Wednesday, 23'rd Aug 2023
AstraZeneca is facing two London lawsuits, including one from the husband of a woman who died after receiving the Anglo-Swedish drugmaker's COVID-19 vaccine, in the first of potentially dozens of case
Is Trending Stock AstraZeneca PLC (AZN) a Buy Now?
07:32pm, Tuesday, 22'nd Aug 2023
Recently, Zacks.com users have been paying close attention to Astrazeneca (AZN). This makes it worthwhile to examine what the stock has in store.
5 Large Drug Stocks to Watch as New Drug Approvals & M&A Gain Pace
11:16am, Monday, 21'st Aug 2023
Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are wo
The 3 Most Undervalued Pharma Stocks to Buy Now: August 2023
05:30am, Monday, 21'st Aug 2023
There are sectors in the economy that go through an extended period of trending sideways to lower. A good example is the pharmaceutical sector.
China's CanSino in mRNA vaccine deal with AstraZeneca
07:35am, Tuesday, 08'th Aug 2023
CanSino Biologics has agreed with AstraZeneca to provide "contract development and manufacturing services" to support the Anglo-Swedish drugmaker's messenger RNA (mRNA) vaccine programme, the Chinese
Is This Blue Chip Dividend Stock a Buy for Growth Investors?
05:20am, Tuesday, 08'th Aug 2023
AstraZeneca's phenomenal medicine portfolio pushed up revenue and profits in the second quarter. The company is committed to innovation.
AstraZeneca is a premium growth story says broker
10:44am, Friday, 04'th Aug 2023
AstraZeneca second indicated to 2023 with eight different medicines delivering over US$1 billion in sales in the first half, notes Shore Capital. AZN also had eight separate Phase III oncology trials
CDC panel says babies should get new drug that prevents RSV
06:35pm, Thursday, 03'rd Aug 2023
Infants should get a new drug to protect them against a respiratory virus that sends tens of thousands of American children to the hospital each year, heath advisers recommended Thursday.
US CDC approves Sanofi-AstraZeneca's preventive RSV therapy for babies
03:32pm, Thursday, 03'rd Aug 2023
The U.S. Centers for Disease Control and Prevention said on Thursday it had approved Sanofi and partner AstraZeneca's antibody therapy to prevent respiratory syncytial virus (RSV) in infants and toddl
3 Pharma Stocks to Buy for Their Promising Progress
05:34am, Monday, 31'st Jul 2023
Identifying promising pharma stocks is no small feat in the dynamic and competitive realm of pharmaceuticals. The industry is replete with businesses boasting robust pipelines, each vying for a breakt
AstraZeneca's Q2 Earnings Exceed Expectations, Astonishing Investors (Rating Upgrade)
01:20am, Sunday, 30'th Jul 2023
AstraZeneca's revenue for the second quarter of 2023 was $11.42 billion, up 5% from the previous quarter and 6% from the second quarter of 2022. At the end of June 2023, AstraZeneca's total debt was a
AstraZeneca reveals a $1.0 billion deal with Pfizer
06:07pm, Saturday, 29'th Jul 2023
AstraZeneca plc (LON: AZN) was in focus on Friday after the pharma giant announced a deal worth up to $1.0 billion with its U.S. peer Pfizer Inc (NYSE: PFE). Details of the AstraZeneca-Pfizer deal The
AstraZeneca PLC (AZN) Q2 2023 Earnings Call Transcript
01:34pm, Friday, 28'th Jul 2023
AstraZeneca PLC (NASDAQ:AZN ) Q2 2023 Earnings Conference Call July 28, 2023 6:45 AM ET Company Participants Andy Barnett - Head, Investor Relations Pascal Soriot - Chief Executive Officer Aradhana Sa
AstraZeneca (AZN) Q2 Earnings & Sales Beat, Nil COVID Sales
01:15pm, Friday, 28'th Jul 2023
AstraZeneca (AZN) beats second-quarter estimates for earnings and sales. The company did not generate any revenues from COVID-19 medications.
